1.18 (-%)
As of Oct 31, 2024
Source:
We are a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S and nelipepimut-S.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | 6462005278 |
| Industry | manufacturing |
| CEO | Angelos M. Stergiou |
| Website | www.sellaslifesciences.com |